APIs, Excipients, and Manufacturing eBook
Read the article:
Global Regulatory Approach to API Manufacturing
Read the ebook:
Pharmaceutical Technology APIs, Excipients, and Manufacturing eBook
Global Regulatory Approach to API Manufacturing
By Meg Rivers
News
Article
Pharmaceutical TechnologyPharmaceutical Technology, APIs, Excipients, and Manufacturing, October 2021
Pages: 18-21
Navigating a complex global regulatory landscape involves upfront research into the expectations of the different regulatory bodies, thorough documentation of every step of the API manufacturing process, and good communication.
AdobeStock_293317053_magele-picture
Prior to the commercialization phase for API manufacturing, there is a lot to juggle as well as a tricky global regulatory landscape to navigate. API manufacturers must meet the standards for the country where the drug will be distributed, and every country has its own regulations as well as its own interpretation of those regulations.
October 2021 API eBook
Read this article in Pharmaceutical Technology’s October 2021 APIs, Excipients, and Manufacturing eBook.
About the author
Meg Rivers is a senior editor for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International.
Article Details
Pharmaceutical Technology
eBook: October 2021
Pages: 18-21
Citation
When referring to this article, please cite it as M. Rivers, “Global Regulatory Approach to API Manufacturing," Pharmaceutical Technology eBook (October 2021).
Articles in this issue
Pharmaceutical Knowledge Management: Experiences in Drug Development and Manufacturing
Shining a Light on Photochemistry in Flow
Predicting Tablet Potency in Continuous Manufacturing
Building Robust Specifications Using Powder Testing
Global Regulatory Approach to API Manufacturing
Seeking Economies of Scale for Biocatalysis
API Development and Manufacturing: Advantages of Working with Small Molecules
Rethinking, Recalibrating, and Retooling
Recent Videos
Related Content
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Article
Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
